• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

1 Biotech That Biogen Should Buy ... but Probably Won't

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 04, 2019 at 11:42: PM
via Biogen's (NASDAQ:BIIB) disclosure that aducanumab doesn't appear to help patients with Alzheimer's disease is a major blow to the big biotech's future growth, especially since its pipeline is fairly limited. The simple solution would be to use the $4.9 billion it had sitting in the bank at the end of 2018 to acquire something -- anything! -- to boost its revenue.

article source
 




Top Bottom
Back
Quote